661:(NIH) for intellectual property related to T cell receptor (TCR)-based product candidates directed against MAGE A3 and A3/A6 antigens for the treatment of tumors expressing MAGE, which include lung, pancreatic, gastric, and breast cancers, among others. In the same month, Kite Pharma announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences (AIS), a privately held biotechnology startup, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. AIS will grant Kite an exclusive license to two programs from its
254:
66:
168:
25:
756:, announced a strategic partnership to create a software solution to support commercial availability of T-cell therapies. Together, the parties will design and develop a platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies if they are FDA-approved, including
1559:
665:(TIP) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates. This collaboration will accelerate Kite's efforts to establish the next generation of engineered T cell therapies specifically designed to overcome the inhibitory mechanisms present in the tumor
592:
Kite Pharma announced findings from its ongoing clinical trial in August: 12 of 13 evaluable patients with advanced B-cell malignancies had complete remissions (8 patients) or partial remissions (4 patients) resulting in a 92% objective response rate. The results support Kite Pharma's plan to file an
873:
to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $ 250 million in payments, of the $ 250 million, Kite said it would receive $ 50 million as upfront payment. Also in
January, Kite Pharma announced that it had formed a joint venture
909:. The three former Kite executives subsequently hired into Allogene a number of people who left Kite after its sale. The notion behind Allogene was to create a 'next generation CAR-T' which was not tailored to a single individual, as YESCARTA was, but rather could be used in multiple patients, an
886:
The company has primary leading manufacturing facilities in El
Segundo, CA next to Los Angeles International airport and Amsterdam, Netherlands to support US, Canada, Australia and European markets. Kite is in the process of coordinating additional manufacturing capacity from its recent expansion
855:(NKI), which include the rights to select new intellectual property related to T-cell receptors (TCRs) developed at the NKI. Additionally, the TCF acquisition will allow Kite Pharma to access the European manufacturing facilities, paving way for the company to initiate development programs in the
729:
In June, Kite Pharma and Cell Design Labs, Inc. announced a research collaboration and license agreement to develop next generation, precision-controlled chimeric antigen receptor (CAR) product candidates that incorporate Cell Design Labs' molecular âon/off switchâ technology. Also in June, Kite
466:
became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This form of immunotherapy was originally developed by the U.S. National Cancer
Institute and the company pays the
461:
announced that it would acquire Kite Pharma for $ 11.9 billion in an all-cash deal, a 29% premium on the share price. Gilead made the purchase in large part to bolster sales in the face of the company's declining hepatitis C franchise revenues, a result of declining patient numbers as they were
685:
announced they will partner to develop a next-generation, functionally integrated and automated manufacturing system for engineered T-cell therapy. Kite and GE Global
ResearchâGE's centralized R&D hubâsaid they aim to increase the availability of engineered T-cell therapies by speeding up
1556:
617:
entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel
Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's extensive array of cancer targets.
850:
In March 2015, Kite Pharma acquired T-Cell
Factory (TCF), a privately held biotechnology company based in the Netherlands, for âŹ20 million and renamed it â Kite Pharma EU. Per the deal, Kite Pharma has obtained license agreements with IBA GmbH, Sanquin Blood Supply Foundation and the
628:, Inc. announced they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor product candidates directed against the human papillomavirus type 16 E6 onco protein incorporating gene editing and lentiviral technologies.
680:
is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemia's. In the same month, Kite Pharma and
1186:
1327:
691:
878:
to develop and commercialize its cancer treatment in China. Kite Pharma said it would receive an upfront payment of $ 40 million from the joint venture, funded by Fosun Pharma as well as regulatory and commercial milestones totaling $ 35 million.
783:
in patients with
Aggressive Non-Hodgkin Lymphoma at the Clinical and Research Excellence Awards. The award recognizes clinical achievements in the pharmaceutical industry and contribution to the advancement of therapies for unmet medical needs.
2421:
1814:
1409:
1099:
1557:"Kite Pharma Announces That the First Patient in Its Phase 1/2 Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, for Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) "
646:. Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer
1187:"Kite's Yescarta⢠(Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy"
882:
On August 28, 2017, Gilead
Sciences announced that it would purchase Kite Pharma for US$ 11.9 billion in cash ($ 180.00 per share). The purchase was subsequently completed for the announced price on October 3, 2017.
1605:
1294:
839:
In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $ 17.00 per share, for gross proceeds of $ 146.6 million. The company listed on the NASDAQ Global market under the symbol âKITE.â
913:
CAR-T. Pfizer received a 25% stake in
Allogene and two seats on the company's board, while Allogene received rights to sixteen pre-clinical CAR-T assets and one Phase 1 allogeneic CAR-T clinical asset. Allogene's
1883:
1936:"Kite Wins âClinical Trial Result of the Yearâ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards"
1721:
702:
In
January, it was announced that Kite Pharma has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19
1744:
1860:
2410:
722:, in order to evaluate the safety and efficacy of two of its novel therapies. The target population for the tests would be patients with non-Hodgkin Lymphoma. The therapies in question, KTE-C19 and
1651:
1767:
1698:
1811:
707:(CAR) product candidate for the treatment of B-cell lymphomas and leukemia. Moreover, Kite Pharma announced that its European subsidiary has entered into a research and license agreement with
745:, on behalf of the University of California, Los Angeles (UCLA), for technology to advance the development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells.
1582:
1401:
1791:
1319:
2263:
2058:
2237:
1837:
1229:
1107:
2105:
1674:
1142:
635:
announced that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive
2517:
730:
Pharma announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the
2537:
2512:
621:
Kite Pharma announced in May, that the first patient in its Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive Non-Hodgkin's Lymphoma has been treated.
1458:"Kite Pharma Announces Exclusive License with The National Institutes of Health for T Cell Receptor (TCR)-Based Products Targeting NY-ESO-1 For Multiple Cancer Indications"
2532:
1602:
672:
In December, Kite Pharma announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with relapsed/refractory acute
1915:
2547:
905:
Following the sale of Kite to Gilead, Kite's founders and its CMO struck a deal in February 2018 with Pfizer to develop CAR-T therapeutics, leading to the creation of
887:
into Urbana, Maryland facility as of 2023 as a strategic center that could accommodate same-day service to both California and Netherlands manufacturing operations.
2522:
1880:
2447:
686:
development of automation technologies that have the potential to lower costs, operate faster, and minimize variability. Also in December, Kite announced that the
1962:
1741:
1540:"Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies"
1718:
1486:
551:
product candidate â KTE-C19 CAR â can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma, known as diffuse
2312:
454:, who served as the company's chairman, president and chief executive officer. Belldegrun had a co-founder in Joshua Kazam, who took on the role of Director.
1857:
1835:"Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)"
1286:
1076:
690:
has granted Breakthrough Therapy Designation status to the company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse
2128:
2008:
1938:
1648:
1628:
1539:
1375:
1349:
2527:
2175:
1764:
1649:"Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE"
1695:
1517:
1376:"Kite Pharma's Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin's Lymphoma"
2336:
1579:
2032:
825:
1788:
748:
In December, Kite Pharma and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company co-founded by
2562:
2557:
2260:
2234:
2055:
2218:
1834:
2382:
1210:
1164:
1765:"Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers"
2542:
178:
2102:
1251:
462:
cured, as Kite's sales were anticipated to reach $ 2 billion per annum. The acquisition was completed in October 2017, when Kite Pharma's
2288:
2198:
2151:
2081:
1985:
1457:
1032:
1671:
515:
1130:
547:
In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite's most advanced
197:
233:
215:
149:
52:
87:
80:
1431:
994:
711:(LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human
708:
704:
507:
1906:
650:
candidates targeting solid tumors. Kite has also expanded its access to additional resources and research facilities through a
519:
735:
712:
2468:
969:
662:
632:
491:(KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory
2357:
741:
In July, Kite Pharma announced that it has entered into an exclusive, worldwide license agreement with The Regents of the
658:
575:
511:
130:
2443:
852:
760:(formerly known as KTE-C19), Kite's lead investigational engineered T-cell therapy for aggressive non-Hodgkin lymphoma.
687:
673:
643:
564:
492:
102:
38:
1959:
1483:
430:
therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in
193:
2309:
2246:
1350:"Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products"
734:(NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human
109:
1983:âKite Pharma Raises $ 15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directorsâ
1066:
76:
731:
536:
496:
2552:
2172:
2125:
2005:
1935:
1625:
1543:
1379:
1353:
923:
742:
651:
598:
594:
1509:
116:
1858:"Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies "
943:
931:
829:
788:
780:
757:
488:
1261:
2333:
1256:
906:
539:
for the development and commercialization of products for the treatment of multiple cancer indications.
472:
98:
2029:
1812:"Kite Pharma (KITE), Cell Design Labs Enter Research Collaboration for Next-Gen CAR Product Candidates"
1432:"Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product"
894:
875:
792:
773:
636:
555:(DLBCL). The clinical data were presented at the 55th American Society of Hematology Annual Meeting.
423:
368:
657:
In October, Kite Pharma announced that it has entered into an exclusive, worldwide license with the
2416:
919:
597:(IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead
552:
522:(TFL). It was approved for use in the United States under the brand name YESCARTA in October 2017.
1216:
844:
682:
1484:"Biotech Stock Kite Pharma Explodes Higher After Good News About Its Non-Hodgkin Lymphoma Drug"
1067:"Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $ 11.9 billion"
535:
In October, Kite Pharma entered into a Cooperative Research and Development Agreement with the
2285:
2195:
2148:
2078:
1982:
1461:
1221:
1071:
1040:
818:
274:
893:
In September 2024, Kite Pharma announced it would sell its 50% stake in the joint venture to
189:
2409:
1696:"Seattleâs Alpine Immune Sciences licenses cancer treatment to Kite Pharma for up to $ 530M"
1495:
915:
779:
In April, Kite has won the âClinical Trial Result of the Yearâ award for its CAR-T trial of
44:
2196:âKite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Sharesâ
1320:"Kite Pharma (KITE) Announces KTE-C19 for NHL Granted FDA Breakthrough Therapy Designation"
503:, a protein expressed on the cell surface of B-cell lymphomas and leukemias. It garnered a
2340:
2316:
2292:
2267:
2241:
2202:
2179:
2155:
2132:
2109:
2085:
2062:
2036:
2012:
1989:
1966:
1942:
1887:
1864:
1841:
1818:
1795:
1771:
1748:
1725:
1702:
1678:
1655:
1632:
1609:
1586:
1563:
1490:
863:
811:
694:, primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL).
579:
458:
447:
435:
314:
302:
123:
1435:
870:
856:
787:
In August, Kite has filed the first CAR-T candidate in Europe, seeking approval of its
385:
2506:
647:
548:
419:
642:
In September, Kite Pharma announced that it has expanded its collaboration with the
833:
723:
625:
431:
325:
253:
2056:"UPDATED: Billionaires back Kite Pharma in $ 20M raise for cancer immunotherapies"
965:
890:
In February 2023, the business completed its acquisition of Tmunity Therapeutics
843:
In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their
753:
749:
568:
65:
2126:âKite Pharma Files Registration Statement for Proposed Initial Public Offeringâ
998:
1603:"Kite Pharma (KITE), Leukemia & Lymphoma Society Enter Into Collaboration"
1402:"Donor-derived allogeneic T cells may cause regression of B-cell malignancies"
910:
738:(HPV)-16 E6 and E7 onco-proteins for the treatment of HPV-associated cancers.
451:
427:
331:
264:
1225:
1131:"Growth-hungry Gilead finally pivots from flagging hep C with $ 12B Kite buy"
1044:
862:
In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a
2261:"Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog"
2041:
930:âand even Gilead as participants, among others. In October 2019, Allogene's
927:
719:
1626:"Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)"
1580:"Kite Pharma & Bluebird Bio To Co-develop T Cell Cell Therapy Products"
574:
In June, Kite Pharma entered into an exclusive, worldwide license with the
495:(ALL)) in which a patient's T cells were genetically modified to express a
1881:"Kite Pharma (KITE) Enters Strategic Partnership with Vitruvian Networks"
1789:"Kite Pharma Inc (NASDAQ:KITE) To Begin a Collaborative Study on KTE-C19"
1719:"Kite Pharma, GE Global Research Partner on T-Cell Therapy Manufacturing"
804:
583:
463:
2469:"Gilead's Kite exits China cell therapy joint venture with Fosun Pharma"
1100:"Gilead to buy Kite for promising cancer therapies in $ 12 billion deal"
810:
In May 2013, Kite Pharma completed a $ 35 million financing of Series A
718:
In March, Kite Pharma has announced that it would be collaborating with
2079:" Kite Pharma, Inc. Completes $ 50 Million Mezzanine Private Financing"
2006:âKite Pharma Completes $ 35 Million Series A Preferred Stock Financingâ
1138:
666:
602:
586:
2272:
504:
1672:"Kite to spend as much as $ 530 million on rights to AIS programs "
426:
products with a primary focus on genetically engineered autologous
2286:"Kite Pharma Announces Pricing of Public Offering of Common Stock"
1742:"Kite Pharma (KITE), NCI Expand Clinical and Research Partnership"
869:
In January 2017, Kite Pharma announced that it has partnered with
769:
614:
476:
ranked Kite Pharma 7th in its annual list of the preceding year's
934:
netted US$ 324 million and a capital valuation of US$ 3 billion.
500:
1510:"Amgen, Kite Pharma ink deal to develop cancer immunotherapies"
1408:. Thorofare, New Jersey: SLACK Incorporated. December 7, 2013.
1211:"Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits"
2310:"Kite Pharma partners with Japan's Daiichi for cancer therapy"
1378:(Press release). Kite Pharma. December 7, 2013. Archived from
1352:(Press release). Kite Pharma. October 16, 2012. Archived from
1287:"Kite Pharma (KITE) Announces Initiation of KTE-C19 Phase 1/2"
348:
161:
59:
18:
2495:
2103:"Immuno-oncology specialist Kite adds $ 50M in new financing"
1542:(Press release). Kite Pharma. January 5, 2015. Archived from
1033:"Allogene TherapeuticsâThe Juggernaut Built On Kite's Flight"
866:
at $ 69.00 per share, for gross proceeds of $ 287.6 million.
847:
at $ 54.00 per share, for gross proceeds of $ 216.4 million.
398:
1434:(Press release). Kite Pharma. March 31, 2014. Archived from
2383:"Gilead Sciences Completes Acquisition of Kite Pharma, Inc"
2173:"Kite Pharma Soars Above IPO Price on First Day of Trading"
1165:"Gilead Sciences Completes Acquisition of Kite Pharma, Inc"
2334:"Kite, Fosun Pharma form JV in China for cancer treatment"
2149:âKite Pharma Announces Pricing of Initial Public Offeringâ
1460:(Press release). Kite Pharma. June 6, 2014. Archived from
571:
designation for the company's proposed therapy for DLBCL.
510:(Dec 2015) for the treatment of patients with refractory
2411:"Kite announces Urbana facility expansion, 100 new jobs"
2235:"Kite Pharma Acquires T-Cell Factory for $ 21M Up Front"
824:
In May 2014, Kite Pharma filed a registration with the
185:
2219:"Kite Pharma Announces Pricing of Follow-On Offering"
768:
In March, Kite announced results a clinical trial of
1208:
Richtel, Matt; Pollack, Andrew (December 19, 2016).
817:
In April 2014, Kite Pharma completed a $ 50 million
803:
In March 2011, Kite Pharma received $ 15 million in
196:, and by adding encyclopedic content written from a
1907:"New gene therapy 'shrinks tumours like ice cubes'"
1098:Grover, Natalie; Erman, Michael (August 28, 2017).
394:
384:
374:
364:
338:
320:
309:
298:
280:
270:
260:
1905:
1209:
726:, would be tested in combination with each other.
589:for the treatment of cancers expressing NY-ESO-1.
1189:(Press release). Gilead Sciences. 18 October 2017
1167:(Press release). Gilead Sciences. October 3, 2017
960:
958:
2299:. 10 December 2015. Retrieved 10 December 2015.
2225:. 10 December 2014. Retrieved 10 December 2015.
1894:. 13 December 2016. Retrieved 14 December 2016.
1639:. 14 September 2015. Retrieved 20 October 2015.
772:cells in around a hundred people with advanced
1314:
1312:
1260:. June 27, 2017. 7 Kite Pharma. Archived from
567:Office of Orphan Products Development granted
2030:"××פ×× ×ץר×× ×Š×¤××Ş× ×ר××××ת × ××Ś× ×××¨× ×× ×ץ×"ק"
1778:. 13 January 2016. Retrieved 13 January 2016.
1732:. 3 December 2015. Retrieved 7 December 2015.
1685:. 28 October 2015. Retrieved 28 October 2015.
1662:. 20 October 2015. Retrieved 20 October 2015.
8:
2518:Pharmaceutical companies established in 2009
2332:Mukhopadhyay, Akankshita (10 January 2017).
2247:Genetic Engineering & Biotechnology News
1960:"Kite files first CAR-T candidate in Europe"
1730:Genetic Engineering & Biotechnology News
1026:
1024:
1022:
1020:
1018:
1016:
578:to certain intellectual property related to
246:
2538:Companies based in Santa Monica, California
2513:Biotechnology companies established in 2009
1755:. 7 January 2015. Retrieved 7 January 2015.
467:government to support continuing research.
53:Learn how and when to remove these messages
582:-based product candidates that target the
354:Mert Aktar (Head of Corporate Development)
252:
245:
2533:Health care companies based in California
2250:. 18 March 2015. Retrieved 18 March 2015.
2209:. 23 June 2014. Retrieved 15 August 2014.
2162:. 20 June 2014. Retrieved 15 August 2014.
1281:
1279:
563:The company announced in March, that the
357:Warner Biddle (Global Head of Commercial)
234:Learn how and when to remove this message
216:Learn how and when to remove this message
150:Learn how and when to remove this message
2389:(Press release). Gilead. October 3, 2017
2019:. 15 May 2013. Retrieved 15 August 2014.
2548:Companies formerly listed on the Nasdaq
2444:"Kite Completes Acquisition of Tmunity"
2092:. 28 April 2014. Retrieved 19 May 2014.
1996:. 9 March 2011. Retrieved 29 July 2014.
1949:. 6 April 2017. Retrieved 7 April 2017.
1871:. 25 July 2016. Retrieved 26 July 2016.
1848:. 20 June 2016. Retrieved 20 June 2016.
989:
987:
954:
688:U.S. Food and Drug Administration (FDA)
565:U.S. Food and Drug Administration (FDA)
2523:American companies established in 2009
1593:. 22 June 2015. Retrieved 7 July 2015.
1330:from the original on December 20, 2019
1297:from the original on December 20, 2019
859:and build its presence in the region.
663:Transmembrane immunomodulatory protein
177:contains content that is written like
86:Please improve this article by adding
2139:. 19 May 2014. Retrieved 19 May 2014.
1825:. 2 June 2016. Retrieved 2 June 2016.
1616:. 1 July 2015. Retrieved 7 July 2015.
1570:. 21 May 2015. Retrieved 7 July 2015.
1520:from the original on December 8, 2015
1252:"What are the 50 Smartest Companies?"
1039:(Online). Pennsylvania: VertMarkets.
7:
2424:from the original on 11 January 2023
1065:Puzzanghera, Jim (August 28, 2017).
2408:Gartner, Emmett (10 January 2023).
2358:"Gilead | Investors | News Release"
972:from the original on March 10, 2023
576:National Institutes of Health (NIH)
516:primary mediastinal B cell lymphoma
446:The company was founded in 2009 by
2045:(Tel Aviv). Retrieved 19 May 2014.
1694:Demmitt, Jacob (28 October 2015).
1412:from the original on March 7, 2016
1232:from the original on June 27, 2022
1079:from the original on June 25, 2022
644:Netherlands Cancer Institute (NKI)
14:
2528:2009 establishments in California
1787:Sandford, Miles (18 March 2016).
1145:from the original on May 15, 2020
434:, California, it was acquired by
34:This article has multiple issues.
2308:Grover, Divya (9 January 2017).
1129:Palmer, Eric (August 28, 2017).
1031:Wright, Rob (January 31, 2020).
709:Leiden University Medical Center
508:Breakthrough Therapy Designation
166:
64:
23:
2450:from the original on 2023-02-27
2171:Calia, Michael (20 June 2014).
2101:Carroll, John (28 April 2014).
1918:from the original on 2017-03-01
918:was US$ 300 million, including
633:Leukemia & Lymphoma Society
537:National Cancer Institute (NCI)
520:transformed follicular lymphoma
499:designed to target the antigen
406:Footnotes / references
42:or discuss these issues on the
2497:Kite Pharma - official website
1958:Taylor, Phil (1 August 2017).
16:American biotechnology company
1:
2563:2017 mergers and acquisitions
2558:2014 initial public offerings
2054:McBride, Ryan (15 May 2013).
1137:. Framingham, Massachusetts:
997:. Kite Pharma. Archived from
692:large B cell lymphoma (DLBCL)
659:National Institutes of Health
631:In July, Kite Pharma and the
512:diffuse large B cell lymphoma
88:secondary or tertiary sources
2347:. Retrieved 10 January 2017.
2323:. Retrieved 10 January 2017.
2028:Orbach, Meir (18 May 2014).
1709:. Retrieved 28 October 2015.
1499:. Retrieved August 27, 2014.
853:Netherlands Cancer Institute
613:In January, Kite Pharma and
493:acute lymphoblastic leukemia
2543:Biopharmaceutical companies
1904:Whipple, Tom (2017-03-01).
1482:Ro, Sam (August 26, 2014).
819:mezzanine private financing
791:(KTE-C19) for two types of
286:; 15 years ago
2579:
2276:. Retrieved 18 March 2015.
2259:Zacks.com (18 March 2015).
1973:. Retrieved 9 August 2017.
1802:. Retrieved 18 March 2016.
605:, in patients with DLBCL.
601:-based product candidate,
2186:. Retrieved 21 June 2014.
1404:. Meeting News Coverage.
732:National Cancer Institute
715:(HPV) type 16 infection.
705:chimeric antigen receptor
652:master services agreement
624:In June, Kite Pharma and
497:chimeric antigen receptor
404:
251:
2116:. Retrieved 19 May 2014.
2069:. Retrieved 19 May 2014.
966:"Kite Pharma LEADERSHIP"
924:University of California
743:University of California
595:Investigational New Drug
2184:The Wall Street Journal
944:Iovance Biotherapeutics
932:initial public offering
830:initial public offering
789:axicabtagene ciloleucel
781:Axicabtagene Ciloleucel
758:axicabtagene ciloleucel
489:Axicabtagene ciloleucel
821:of convertible notes.
793:non-Hodgkin's lymphoma
637:Non-Hodgkin's Lymphoma
450:, an Israeli-American
422:company that develops
75:relies excessively on
1257:MIT Technology Review
907:Allogene Therapeutics
901:Allogene Therapeutics
871:Daiichi Sankyo Co Ltd
553:large B cell lymphoma
478:50 Smartest Companies
473:MIT Technology Review
198:neutral point of view
2362:investors.gilead.com
1546:on January 21, 2015.
1326:. December 7, 2015.
1293:. December 2, 2015.
1264:on November 12, 2017
1110:on September 2, 2017
895:Fosun Pharmaceutical
876:Fosun Pharmaceutical
774:Non-Hodgkin lymphoma
457:On August 28, 2017,
424:cancer immunotherapy
369:Cancer immunotherapy
2417:Frederick News-Post
1516:. January 5, 2015.
1438:on January 12, 2015
1037:Life Science Leader
920:Texas Pacific Group
526:Development history
409:Key People, Founder
376:Number of employees
248:
190:promotional content
2339:2017-01-11 at the
2315:2017-01-12 at the
2291:2015-12-22 at the
2266:2015-03-20 at the
2240:2015-03-23 at the
2201:2014-07-17 at the
2178:2014-06-22 at the
2154:2014-08-11 at the
2131:2014-08-09 at the
2108:2014-05-19 at the
2084:2014-08-11 at the
2061:2014-05-19 at the
2035:2014-05-19 at the
2011:2014-08-09 at the
1988:2014-08-11 at the
1965:2017-08-09 at the
1941:2017-04-07 at the
1886:2016-12-20 at the
1863:2016-07-26 at the
1840:2016-06-21 at the
1817:2016-06-03 at the
1800:Journal Transcript
1794:2016-03-18 at the
1770:2016-01-15 at the
1747:2016-03-04 at the
1724:2015-12-07 at the
1701:2015-10-28 at the
1677:2015-12-08 at the
1654:2015-10-23 at the
1631:2015-12-08 at the
1608:2015-07-08 at the
1585:2015-07-08 at the
1562:2015-07-08 at the
1489:2014-08-27 at the
1464:on August 11, 2014
1217:The New York Times
968:. March 10, 2023.
897:for $ 27 million.
845:follow-on offering
683:GE Global Research
399:www.kitepharma.com
192:and inappropriate
1892:StreetInsider.com
1823:StreetInsider.com
1614:StreetInsider.com
1382:on August 9, 2014
1356:on August 9, 2014
1324:StreetInsider.com
1291:StreetInsider.com
1072:Los Angeles Times
995:"Management Team"
667:micro-environment
413:
412:
275:Biopharmaceutical
247:Kite Pharma, Inc.
244:
243:
236:
226:
225:
218:
160:
159:
152:
134:
57:
2570:
2484:
2483:
2481:
2479:
2465:
2459:
2458:
2456:
2455:
2440:
2434:
2433:
2431:
2429:
2413:
2405:
2399:
2398:
2396:
2394:
2379:
2373:
2372:
2370:
2369:
2354:
2348:
2330:
2324:
2306:
2300:
2283:
2277:
2257:
2251:
2232:
2226:
2216:
2210:
2193:
2187:
2169:
2163:
2146:
2140:
2123:
2117:
2099:
2093:
2076:
2070:
2052:
2046:
2026:
2020:
2003:
1997:
1980:
1974:
1956:
1950:
1933:
1927:
1926:
1924:
1923:
1909:
1901:
1895:
1878:
1872:
1855:
1849:
1832:
1826:
1809:
1803:
1785:
1779:
1762:
1756:
1739:
1733:
1716:
1710:
1692:
1686:
1669:
1663:
1646:
1640:
1623:
1617:
1600:
1594:
1577:
1571:
1554:
1548:
1547:
1536:
1530:
1529:
1527:
1525:
1506:
1500:
1496:Business Insider
1480:
1474:
1473:
1471:
1469:
1454:
1448:
1447:
1445:
1443:
1428:
1422:
1421:
1419:
1417:
1398:
1392:
1391:
1389:
1387:
1372:
1366:
1365:
1363:
1361:
1346:
1340:
1339:
1337:
1335:
1316:
1307:
1306:
1304:
1302:
1283:
1274:
1273:
1271:
1269:
1248:
1242:
1241:
1239:
1237:
1213:
1205:
1199:
1198:
1196:
1194:
1183:
1177:
1176:
1174:
1172:
1161:
1155:
1154:
1152:
1150:
1126:
1120:
1119:
1117:
1115:
1106:. Archived from
1095:
1089:
1088:
1086:
1084:
1062:
1056:
1055:
1053:
1051:
1028:
1011:
1010:
1008:
1006:
1001:on July 17, 2017
991:
982:
981:
979:
977:
962:
916:Series A funding
799:Business history
676:leukemia (ALL).
305:and Joshua Kazam
294:
292:
287:
256:
249:
239:
232:
221:
214:
210:
207:
201:
179:an advertisement
170:
169:
162:
155:
148:
144:
141:
135:
133:
92:
68:
60:
49:
27:
26:
19:
2578:
2577:
2573:
2572:
2571:
2569:
2568:
2567:
2553:Gilead Sciences
2503:
2502:
2492:
2487:
2477:
2475:
2467:
2466:
2462:
2453:
2451:
2442:
2441:
2437:
2427:
2425:
2407:
2406:
2402:
2392:
2390:
2381:
2380:
2376:
2367:
2365:
2364:(Press release)
2356:
2355:
2351:
2341:Wayback Machine
2331:
2327:
2317:Wayback Machine
2307:
2303:
2293:Wayback Machine
2284:
2280:
2268:Wayback Machine
2258:
2254:
2242:Wayback Machine
2233:
2229:
2217:
2213:
2203:Wayback Machine
2194:
2190:
2180:Wayback Machine
2170:
2166:
2156:Wayback Machine
2147:
2143:
2133:Wayback Machine
2124:
2120:
2110:Wayback Machine
2100:
2096:
2086:Wayback Machine
2077:
2073:
2063:Wayback Machine
2053:
2049:
2037:Wayback Machine
2027:
2023:
2013:Wayback Machine
2004:
2000:
1990:Wayback Machine
1981:
1977:
1967:Wayback Machine
1957:
1953:
1943:Wayback Machine
1934:
1930:
1921:
1919:
1903:
1902:
1898:
1888:Wayback Machine
1879:
1875:
1865:Wayback Machine
1856:
1852:
1842:Wayback Machine
1833:
1829:
1819:Wayback Machine
1810:
1806:
1796:Wayback Machine
1786:
1782:
1772:Wayback Machine
1763:
1759:
1749:Wayback Machine
1740:
1736:
1726:Wayback Machine
1717:
1713:
1703:Wayback Machine
1693:
1689:
1683:ThePharmaLetter
1679:Wayback Machine
1670:
1666:
1656:Wayback Machine
1647:
1643:
1633:Wayback Machine
1624:
1620:
1610:Wayback Machine
1601:
1597:
1587:Wayback Machine
1578:
1574:
1564:Wayback Machine
1555:
1551:
1538:
1537:
1533:
1523:
1521:
1508:
1507:
1503:
1491:Wayback Machine
1481:
1477:
1467:
1465:
1456:
1455:
1451:
1441:
1439:
1430:
1429:
1425:
1415:
1413:
1400:
1399:
1395:
1385:
1383:
1374:
1373:
1369:
1359:
1357:
1348:
1347:
1343:
1333:
1331:
1318:
1317:
1310:
1300:
1298:
1285:
1284:
1277:
1267:
1265:
1250:
1249:
1245:
1235:
1233:
1207:
1206:
1202:
1192:
1190:
1185:
1184:
1180:
1170:
1168:
1163:
1162:
1158:
1148:
1146:
1128:
1127:
1123:
1113:
1111:
1097:
1096:
1092:
1082:
1080:
1064:
1063:
1059:
1049:
1047:
1030:
1029:
1014:
1004:
1002:
993:
992:
985:
975:
973:
964:
963:
956:
952:
940:
903:
864:public offering
812:preferred stock
801:
766:
700:
611:
561:
545:
533:
528:
486:
459:Gilead Sciences
448:Arie Belldegrun
444:
436:Gilead Sciences
418:is an American
408:
390:Gilead Sciences
377:
360:
341:
334:
328:
315:Gilead Sciences
303:Arie Belldegrun
290:
288:
285:
240:
229:
228:
227:
222:
211:
205:
202:
183:
171:
167:
156:
145:
139:
136:
93:
91:
85:
81:primary sources
69:
28:
24:
17:
12:
11:
5:
2576:
2574:
2566:
2565:
2560:
2555:
2550:
2545:
2540:
2535:
2530:
2525:
2520:
2515:
2505:
2504:
2501:
2500:
2491:
2490:External links
2488:
2486:
2485:
2460:
2435:
2400:
2374:
2349:
2325:
2301:
2278:
2252:
2227:
2211:
2188:
2164:
2141:
2118:
2094:
2071:
2047:
2021:
1998:
1975:
1951:
1928:
1896:
1873:
1850:
1827:
1804:
1780:
1757:
1734:
1711:
1687:
1664:
1660:FiereceBiotech
1641:
1618:
1595:
1572:
1549:
1531:
1501:
1475:
1449:
1423:
1393:
1367:
1341:
1308:
1275:
1243:
1200:
1178:
1156:
1121:
1090:
1057:
1012:
983:
953:
951:
948:
947:
946:
939:
936:
902:
899:
807:venture cash.
800:
797:
765:
762:
736:papillomavirus
713:papillomavirus
699:
696:
654:with the NKI.
610:
607:
560:
557:
544:
541:
532:
529:
527:
524:
485:
482:
443:
440:
411:
410:
402:
401:
396:
392:
391:
388:
382:
381:
378:
375:
372:
371:
366:
362:
361:
359:
358:
355:
352:
347:Christi Shaw (
344:
342:
339:
336:
335:
330:
324:
322:
318:
317:
311:
307:
306:
300:
296:
295:
282:
278:
277:
272:
268:
267:
262:
258:
257:
242:
241:
224:
223:
194:external links
174:
172:
165:
158:
157:
72:
70:
63:
58:
32:
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
2575:
2564:
2561:
2559:
2556:
2554:
2551:
2549:
2546:
2544:
2541:
2539:
2536:
2534:
2531:
2529:
2526:
2524:
2521:
2519:
2516:
2514:
2511:
2510:
2508:
2499:
2498:
2494:
2493:
2489:
2474:
2470:
2464:
2461:
2449:
2445:
2439:
2436:
2423:
2419:
2418:
2412:
2404:
2401:
2388:
2384:
2378:
2375:
2363:
2359:
2353:
2350:
2346:
2342:
2338:
2335:
2329:
2326:
2322:
2318:
2314:
2311:
2305:
2302:
2298:
2294:
2290:
2287:
2282:
2279:
2275:
2274:
2269:
2265:
2262:
2256:
2253:
2249:
2248:
2243:
2239:
2236:
2231:
2228:
2224:
2220:
2215:
2212:
2208:
2204:
2200:
2197:
2192:
2189:
2185:
2181:
2177:
2174:
2168:
2165:
2161:
2157:
2153:
2150:
2145:
2142:
2138:
2134:
2130:
2127:
2122:
2119:
2115:
2114:FierceBiotech
2111:
2107:
2104:
2098:
2095:
2091:
2087:
2083:
2080:
2075:
2072:
2068:
2067:FierceBiotech
2064:
2060:
2057:
2051:
2048:
2044:
2043:
2039:(In Hebrew).
2038:
2034:
2031:
2025:
2022:
2018:
2014:
2010:
2007:
2002:
1999:
1995:
1991:
1987:
1984:
1979:
1976:
1972:
1968:
1964:
1961:
1955:
1952:
1948:
1947:Yahoo Finance
1944:
1940:
1937:
1932:
1929:
1917:
1913:
1908:
1900:
1897:
1893:
1889:
1885:
1882:
1877:
1874:
1870:
1866:
1862:
1859:
1854:
1851:
1847:
1843:
1839:
1836:
1831:
1828:
1824:
1820:
1816:
1813:
1808:
1805:
1801:
1797:
1793:
1790:
1784:
1781:
1777:
1776:FierceBiotech
1773:
1769:
1766:
1761:
1758:
1754:
1753:TheStreet.com
1750:
1746:
1743:
1738:
1735:
1731:
1727:
1723:
1720:
1715:
1712:
1708:
1704:
1700:
1697:
1691:
1688:
1684:
1680:
1676:
1673:
1668:
1665:
1661:
1657:
1653:
1650:
1645:
1642:
1638:
1634:
1630:
1627:
1622:
1619:
1615:
1611:
1607:
1604:
1599:
1596:
1592:
1588:
1584:
1581:
1576:
1573:
1569:
1565:
1561:
1558:
1553:
1550:
1545:
1541:
1535:
1532:
1519:
1515:
1511:
1505:
1502:
1498:
1497:
1492:
1488:
1485:
1479:
1476:
1463:
1459:
1453:
1450:
1437:
1433:
1427:
1424:
1411:
1407:
1403:
1397:
1394:
1381:
1377:
1371:
1368:
1355:
1351:
1345:
1342:
1329:
1325:
1321:
1315:
1313:
1309:
1296:
1292:
1288:
1282:
1280:
1276:
1263:
1259:
1258:
1253:
1247:
1244:
1231:
1227:
1223:
1219:
1218:
1212:
1204:
1201:
1188:
1182:
1179:
1166:
1160:
1157:
1144:
1140:
1136:
1135:Fierce Pharma
1132:
1125:
1122:
1109:
1105:
1101:
1094:
1091:
1078:
1074:
1073:
1068:
1061:
1058:
1046:
1042:
1038:
1034:
1027:
1025:
1023:
1021:
1019:
1017:
1013:
1000:
996:
990:
988:
984:
971:
967:
961:
959:
955:
949:
945:
942:
941:
937:
935:
933:
929:
925:
921:
917:
912:
908:
900:
898:
896:
891:
888:
884:
880:
877:
872:
867:
865:
860:
858:
854:
848:
846:
841:
837:
835:
832:(IPO) of its
831:
827:
822:
820:
815:
813:
808:
806:
798:
796:
794:
790:
785:
782:
777:
775:
771:
763:
761:
759:
755:
751:
746:
744:
739:
737:
733:
727:
725:
721:
716:
714:
710:
706:
697:
695:
693:
689:
684:
679:
675:
674:lymphoblastic
670:
668:
664:
660:
655:
653:
649:
648:immunotherapy
645:
640:
638:
634:
629:
627:
622:
619:
616:
608:
606:
604:
600:
596:
590:
588:
585:
581:
577:
572:
570:
566:
558:
556:
554:
550:
549:immunotherapy
542:
540:
538:
530:
525:
523:
521:
518:(PMBCL), and
517:
513:
509:
506:
502:
498:
494:
490:
483:
481:
479:
475:
474:
468:
465:
460:
455:
453:
449:
441:
439:
437:
433:
429:
425:
421:
420:biotechnology
417:
407:
403:
400:
397:
393:
389:
387:
383:
379:
373:
370:
367:
363:
356:
353:
350:
346:
345:
343:
337:
333:
327:
323:
319:
316:
312:
308:
304:
301:
297:
283:
279:
276:
273:
269:
266:
263:
259:
255:
250:
238:
235:
220:
217:
209:
199:
195:
191:
187:
181:
180:
175:This article
173:
164:
163:
154:
151:
143:
132:
129:
125:
122:
118:
115:
111:
108:
104:
101: â
100:
99:"Kite Pharma"
96:
95:Find sources:
89:
83:
82:
78:
73:This article
71:
67:
62:
61:
56:
54:
47:
46:
41:
40:
35:
30:
21:
20:
2496:
2478:20 September
2476:. Retrieved
2473:Fiercepharma
2472:
2463:
2452:. Retrieved
2438:
2426:. Retrieved
2415:
2403:
2391:. Retrieved
2386:
2377:
2366:. Retrieved
2361:
2352:
2344:
2328:
2320:
2304:
2296:
2281:
2271:
2255:
2245:
2230:
2222:
2214:
2206:
2191:
2183:
2167:
2159:
2144:
2136:
2121:
2113:
2097:
2089:
2074:
2066:
2050:
2040:
2024:
2017:Kite Pharma
2016:
2001:
1994:Kite Pharma
1993:
1978:
1970:
1954:
1946:
1931:
1920:. Retrieved
1911:
1899:
1891:
1876:
1869:BusinessWire
1868:
1853:
1846:BusinessWire
1845:
1830:
1822:
1807:
1799:
1783:
1775:
1760:
1752:
1737:
1729:
1714:
1706:
1690:
1682:
1667:
1659:
1644:
1636:
1621:
1613:
1598:
1590:
1575:
1567:
1552:
1544:the original
1534:
1522:. Retrieved
1513:
1504:
1494:
1478:
1466:. Retrieved
1462:the original
1452:
1440:. Retrieved
1436:the original
1426:
1416:December 19,
1414:. Retrieved
1405:
1396:
1384:. Retrieved
1380:the original
1370:
1358:. Retrieved
1354:the original
1344:
1334:December 19,
1332:. Retrieved
1323:
1301:December 19,
1299:. Retrieved
1290:
1268:December 19,
1266:. Retrieved
1262:the original
1255:
1246:
1234:. Retrieved
1215:
1203:
1191:. Retrieved
1181:
1171:December 19,
1169:. Retrieved
1159:
1149:December 19,
1147:. Retrieved
1134:
1124:
1114:December 19,
1112:. Retrieved
1108:the original
1103:
1093:
1081:. Retrieved
1070:
1060:
1050:February 15,
1048:. Retrieved
1036:
1003:. Retrieved
999:the original
974:. Retrieved
904:
892:
889:
885:
881:
868:
861:
849:
842:
838:
834:common stock
823:
816:
809:
802:
786:
778:
767:
747:
740:
728:
724:atezolizumab
717:
701:
677:
671:
656:
641:
630:
626:bluebird bio
623:
620:
612:
591:
573:
562:
546:
534:
487:
484:Lead product
477:
471:
469:
456:
445:
432:Santa Monica
415:
414:
405:
326:Santa Monica
321:Headquarters
313:Acquired by
261:Company type
230:
212:
203:
188:by removing
184:Please help
176:
146:
137:
127:
120:
113:
106:
94:
74:
50:
43:
37:
36:Please help
33:
2207:Kite Pharma
2160:Kite Pharma
2137:Kite Pharma
2090:Kite Pharma
1637:Kite Pharma
1568:MarketWatch
1524:January 21,
754:Mayo Clinic
750:GE Ventures
569:orphan drug
416:Kite Pharma
206:August 2018
140:August 2018
2507:Categories
2454:2023-02-27
2428:10 January
2368:2017-08-28
1922:2017-03-01
1386:August 15,
1360:August 15,
950:References
911:allogeneic
452:oncologist
428:CAR T cell
340:Key people
332:California
265:Subsidiary
186:improve it
110:newspapers
77:references
39:improve it
2042:Calcalist
1912:The Times
1226:0362-4331
1045:2161-0800
976:March 10,
928:Two River
720:Genentech
514:(DLBCL),
470:In 2017,
438:in 2017.
45:talk page
2448:Archived
2422:Archived
2387:Newsroom
2337:Archived
2313:Archived
2289:Archived
2264:Archived
2238:Archived
2199:Archived
2176:Archived
2152:Archived
2129:Archived
2106:Archived
2082:Archived
2059:Archived
2033:Archived
2009:Archived
1986:Archived
1963:Archived
1939:Archived
1916:Archived
1884:Archived
1861:Archived
1838:Archived
1815:Archived
1792:Archived
1768:Archived
1745:Archived
1722:Archived
1707:GeekWire
1699:Archived
1675:Archived
1652:Archived
1629:Archived
1606:Archived
1583:Archived
1560:Archived
1518:Archived
1487:Archived
1410:Archived
1328:Archived
1295:Archived
1236:July 13,
1230:Archived
1143:Archived
1083:July 13,
1077:Archived
970:Archived
938:See also
805:Series A
752:and the
584:NY-ESO-1
464:Yescarta
365:Products
271:Industry
2345:Reuters
2321:Reuters
2297:Reuters
2223:Reuters
1514:Reuters
1468:June 8,
1442:May 19,
1139:Questex
1104:Reuters
1005:June 2,
828:for an
795:(NHL).
678:KTE-C19
603:KTE-C19
587:antigen
442:History
395:Website
299:Founder
289: (
281:Founded
124:scholar
2393:15 Feb
2273:NASDAQ
1971:PMLive
1591:NASDAQ
1406:Healio
1224:
1193:19 Dec
1043:
505:US FDA
386:Parent
126:
119:
112:
105:
97:
874:with
770:CAR-T
615:Amgen
380:2,000
131:JSTOR
117:books
2480:2024
2430:2023
2395:2020
1526:2015
1470:2014
1444:2014
1418:2019
1388:2014
1362:2014
1336:2019
1303:2019
1270:2019
1238:2022
1222:ISSN
1195:2019
1173:2019
1151:2019
1116:2019
1085:2022
1052:2020
1041:ISSN
1007:2016
978:2023
764:2017
698:2016
609:2015
559:2014
543:2013
531:2012
501:CD19
310:Fate
291:2009
284:2009
103:news
826:SEC
599:CAR
580:TCR
349:CEO
79:to
2509::
2471:.
2446:.
2420:.
2414:.
2385:.
2360:.
2343:.
2319:.
2295:.
2270:.
2244:.
2221:.
2205:.
2182:.
2158:.
2135:.
2112:.
2088:.
2065:.
2015:.
1992:.
1969:.
1945:.
1914:.
1910:.
1890:.
1867:.
1844:.
1821:.
1798:.
1774:.
1751:.
1728:.
1705:.
1681:.
1658:.
1635:.
1612:.
1589:.
1566:.
1512:.
1493:.
1322:.
1311:^
1289:.
1278:^
1254:.
1228:.
1220:.
1214:.
1141:.
1133:.
1102:.
1075:.
1069:.
1035:.
1015:^
986:^
957:^
926:,
922:,
857:EU
836:.
814:.
776:.
669:.
639:.
480:.
329:,
90:.
48:.
2482:.
2457:.
2432:.
2397:.
2371:.
1925:.
1528:.
1472:.
1446:.
1420:.
1390:.
1364:.
1338:.
1305:.
1272:.
1240:.
1197:.
1175:.
1153:.
1118:.
1087:.
1054:.
1009:.
980:.
351:)
293:)
237:)
231:(
219:)
213:(
208:)
204:(
200:.
182:.
153:)
147:(
142:)
138:(
128:¡
121:¡
114:¡
107:¡
84:.
55:)
51:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
